Turquoise

Price Transparency drug reimbursement data has rapidly evolved from "what is in this data?" to "this is a strategic & operational imperative!" for leading drug manufacturers. After discussions with 100+ manufacturers within market access, pricing, HEOR and account/FRMs, core themes evolved around: - reimbursement by therapeutic class (incl. brands vs biosimilars) - reimbursement by provider site of care (incl. Hospital vs Specialty vs ASOC) - reimbursement by policy & line of business (incl. Medicare, Medicaid, Commercial) - reimbursement by geographic factors and market control dynamics In partnership with ZS, we decided to deep dive into these questions across 4 therapeutic areas and 17 physician administered drugs. If you'd rather listen than read, we're hosting a webinar to take you behind the scenes and cover all the key takeaways. We're working on the slides as we speak! Here's one of my favorites looking at trends of commercial reimbursement by sites of care. Here's a behind the scenes look on what we're drafting up (below). Join us on 10/28 for a look behind the report and a chance to ask us questions. Here's the link to register: https://lnkd.in/g8ukzwah Mischka Moechtar, #marketaccess, #drugpricing, #drugreimbursement, #HEOR

Month 1 with AI looks like data lookups. Month 6 looks like walking into a payer negotiation already knowing where you win.

The work you've been outsourcing to consultants? Your team can now do it in-house, on demand.

Your peers started using AI for rate benchmarking. Then they realized what else it could do. Here's the data.

Six months of real AI usage data from managed care teams reveals one thing: it's all about contracts

60% of managed care AI queries are contract-related. Here's what health systems are actually doing with it.